1. Contract manufacturing giant WuXi Bio's stock plummets as it warns of $400M revenue miss
WuXi Biologics’ stock price plummeted about 24% Monday after the CDMO giant said it expects to miss this year’s revenue target by around $400 million. The company pointed to an industrywide downturn in COVID-related sales and challenges in biotech funding. The biologics manufacturer views the first half of 2024 as its darkest hours, with a positive turnaround in the second half of next year.
4. Novartis expands radiotherapy manufacturing network with $85M plant in China
Novartis has unveiled a plan to build a new radiotherapy manufacturing facility in China with an investment of about $85 million. The new plant, located in Haiyan about 60 miles from Shanghai, is expected to be operational for local production in 2026. The Chinese project adds to Novartis’ existing radiotherapy facilities in Italy, Spain and the U.S.
5. High-flying Fujifilm splashes $200M to beef up cell therapy capacity
Fujifilm plans to spend $200 million between Fujifilm Cellular Dynamics and Fujifilm Diosynth Biotechnologies to expand its cell therapy capabilities. The former subsidiary, focused on human induced pluripotent stem cells, will get a new headquarters in Madison, Wisconsin; and the latter CDMO will expand an existing site in Thousand Oaks, California.
6. South Africa's Aspen expands reach with $100M buy of Sandoz's Chinese business
Sandoz is selling its China business to South Africa’s Aspen Pharmacare for about $100 million, with about $20 million tied to the future performance of Sandoz’s pipeline products. Aspen expects the deal to add about $96 million in annual sales, with such products such as the synthetic hormone injectable Sandostatin.
7. Tang Capital’s Concentra back with another buyout offer, this time for LianBio
LianBio has rejected an unsolicited buyout proposal by Tang Capital Partners’ Concentra Biosciences, saying the deal terms undervalue the company. LianBio, built on a business model of bringing innovative drugs to China and other Asian markets, recently launched a strategic review and sold certain Asian rights to mavacamten to Bristol Myers Squibb for $350 million.
Other News of Note:
8. FDA recommends avoiding plastic syringes made in China amid safety investigation
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.